Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control
In parallel with their development of the first synthetic gene drives – which greatly increase the chance a specific gene will be passed on to all offspring – George Church, Ph.D., and Kevin Esvelt, Ph.D., helped pioneer proactive biosafety measures to ensure that gene drives are investigated effectively and safely in confined laboratory experiments. They envision that synthetic gene drives designed using an RNA-guided gene editing system known as CRISPR-Cas9 – which works like a pair of molecular scissors to precisely cut or edit DNA – could one day be used outside of the lab to prevent transmission of deadly insect and animal-borne diseases and eradicate invasive species that threaten the ecosystem and agriculture.
Now, in a new study published in Nature Biotechnology on November 16, a team led by Church and Esvelt at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) demonstrates effective safeguarding mechanisms for working with gene drives and unveils a first-of-its-kind method for reversing the changes they spread.
“Any claim of reversibility of modern technology requires strong evidence,” said Church, who is a Wyss Core Faculty member, the Robert Winthrop Professor of Genetics at HMS, and Professor of Health Sciences and Technology at Harvard and MIT. “This is a major step in that direction for the field of synthetic biology.”
Alongside researchers on the Wyss Institute’s Synthetic Biology platform, Church and Esvelt, who is a Wyss Technology Development Fellow, have led the gene drive research community in discussions about responsible laboratory conduct and proactive confinement guidelines for the safeguarding of gene drive research. Their latest study verifies the efficacy of safeguarding protocols developed by their team, such as increased and improved physical biocontainment barriers and the introduction of so-called “molecular confinement” mechanisms which use genetic engineering to block laboratory organisms from surviving and reproducing in the highly unlikely event they ever escaped into the ecosystem.
“The gene drive research community has been actively discussing what should be done to safeguard shared ecosystems, and now we have demonstrated that the proposed safeguards work extremely well and should therefore be used by every gene drive researcher in every relevant lab organism,” said Esvelt.
CRISPR gene drives work by using sequences of RNA to guide the gene-cutting Cas9 protein to a specific target gene for editing. The molecular confinement mechanisms developed by the team prevent gene drives from functioning in the wild by manipulating these biological components. By separating the guide RNA and the Cas9 protein so that they are not encoded together in the same organism, or by inserting an artificial sequence into the targeted gene, gene drives can only be activated in lab organisms and are therefore not able to function in the wild.
“Using yeast in the lab, we also showed that a trait imposed on a population using a gene drive could be reversed,” said the paper’s first co-first author James Dicarlo, a graduate research assistant at the Wyss Institute and HMS. The team notes that using this safeguard, essentially any population-level change mediated by a gene drive could be subsequently overwritten if the need ever arose. In such a case, the originally imposed trait would be reversed and the biological “machinery” of the CRISPR gene drive system – the guide RNAs and the Cas9 protein – would remain present, albeit rendered inactive, in the DNA of organisms.
The reversibility mechanism isn’t just a useful backup to have on hand in case a gene drive ever had an unexpected side-effect; the ability to impose or reverse gene drive effects could also one day prove useful for the management of disease transmitting organisms such as mosquitoes, invasive species, and crop-destroying insects.
Although more research needs to be done in the lab before gene drives will ever potentially be ready for use outside of confined laboratory experiments, researchers now have the tools to perform those experiments safely. And in the meantime, gene drives themselves are useful lab tools for perturbing the genomes of lab organisms and unlocking new insights into the complex interplay of genes.
Read more: Gene drive reversibility introduces new layer of biosafety
The Latest on: Gene drives
via Google News
The Latest on: Gene drives
- GLOBAL STREAMING SERVICE STARZ ANNOUNCES PLANS TO EXPAND LIONSGATE PLAY INTO INDONESIA WITH KEY EXECUTIVE HIRES GUNTUR SIBORO AND GENE TAMESISon January 20, 2021 at 10:13 pm
Starz, one of the leading premium global streaming platforms, today announced plans to expand its global reach into Indonesia with its premium OTT platform Lionsgate Play. Guntur Siboro has been hired ...
- Overuse of antibiotics for meat production drives resistance in humanson January 20, 2021 at 8:05 pm
Mention antibiotic resistance and few people would link what is increasingly being recognised as a growing global health crisis with a Big Mac. But in the US, animals farmed for food account for most ...
- Hemophilia Gene Therapy Market Report Examines Analysis By Latest Trends, Growth Factors, Key Players And Forecast To 2028on January 19, 2021 at 1:33 pm
The global haemophilia gene therapy market is expected to grow with a significant CAGR over the forecast period. The global market report covers the product type, market study based on applications ...
- Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatmenton January 19, 2021 at 5:41 am
Drugs that target the cancer-promoting proteins MDM2 and BET have been tried in acute myeloid leukemia (AML) but haven’t been all that effective on their own. In a new study, combining the two ...
- Gene Synthesis Market to Exhibit Remarkable CAGR of 20% through 2029 – Future Market Insightson January 19, 2021 at 5:40 am
The global gene synthesis market will expand at an exponential 20% CAGR through 2029. According to a new study by Future Market Insights (FMI), the market ...
- Gene Therapy for Rare Diseases: Strategies to Drive Operations, Upcoming Webinar Hosted by Xtalkson January 17, 2021 at 10:30 am
In this free webinar, the featured speakers will discuss the scientific, clinical, regulatory and operational complexities specific to rare disease clinical development. Attendees will learn how to ...
- Triangle’s gene therapy hub has another rising star: Atsena, targeting blindnesson January 15, 2021 at 8:40 am
Meet Atsena Therapeutics – a clinical-stage gene therapy company headquartered in Durham that's on a mission to reverse and prevent blindness.
- FDA, USDA still at odds regarding livestock gene-editingon January 14, 2021 at 8:40 am
NPPC offers initial comments on USDA’s rulemaking for gene-edited livestock species. In public comments earlier this week, the current Food and Drug Administration Commissioner Dr. Stephen Hahn says ...
- Gene Panel Market Sales Insights, Growth Outlook, Share Value, Future Trends, Cost Analysis By 2025on January 13, 2021 at 10:14 am
A gene panel is a type of test that helps to analyze multiple genes at the same time for cancer-associated mutations.
- HTR2A Gene Changes Found Only in Progressive MS May Be New Biomarkeron January 13, 2021 at 7:53 am
Scientists have discovered epigenetic changes in a gene called HTR2A, found only in immune cells isolated from people with secondary progressive multiple sclerosis (SPMS), a study reported. These ...
via Bing News